Amgen Inc.
NASDAQ:AMGNDrug Manufacturers - General
-$6.93 today
- Market cap
- $240.11B
- Beta
- 0.42
- P/E (TTM)
- 23.2
- EPS (TTM)
- $14.44
- Dividend yield
- 2.93%
Volume 2.58M
Average 2.76M
AMGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Amgen Inc.NASDAQ: AMGN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $1.87B rose 7.1% year over year, behind the +19.3% change in trailing-twelve-month research & development. Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.
Context
- Research & development amounted to 19.0% of revenue in FY2025, up 1.1 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +7.1% toward the trailing-twelve-month pace of +19.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.97B USD
- Year-over-year change
- +16.9%
- 4-year CAGR
- +2.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.97B | +16.9% |
| FY2024 | 2024-12-31 | 5.96B | +24.7% |
| FY2023 | 2023-12-31 | 4.78B | +7.9% |
| FY2022 | 2022-12-31 | 4.43B | -29.9% |
| FY2021 | 2021-12-31 | 6.32B | — |
Research & Development vs competitors
How AMGN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19.3% is the 4th highest of 10, against a peer median of +7.0%.
- Research & development amounts to 20.0% of revenue for AMGN, versus a peer median of 20.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $28.35B USD | +65.7% | -2.6% | 42.7% | |
| LTM Sep 2026 | $16.08B USD | +2.4% | +1.2% | 16.2% | |
| LTM Sep 2026 | $15.01B USD | -0.3% | +13.4% | 24.1% | |
| LTM Jun 2026 | $14.6B USD | +23.4% | +22.9% | 18.3% | |
| LTM Jun 2026 | $11.28B USD | +9.2% | +5.4% | 20.3% | |
| LTM Jun 2026 | $11.05B USD | +7.0% | -3.0% | 17.3% | |
| LTM Jun 2026 | $10.72B USD | +3.1% | +1.5% | 21.8% | |
| LTM Sep 2026 | $9.96B USD | -25.0% | +11.8% | 15.1% | |
| LTM Jun 2026 | £9.2B GBP | +31.8% | +11.1% | 27.7% | |
| LTM Jun 2026 | $7.64B USD | +19.3% | +16.3% | 20.0% | |
| Peer median (excluding AMGN) | — | +7.0% | +5.4% | 20.3% | |
Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.98B | 26.32B | 28.19B | 33.42B | 36.74B |
| Cost of Revenue | 6.45B | 6.41B | 8.42B | 12.86B | 10.73B |
| Gross Profit | 19.53B | 19.92B | 19.78B | 20.57B | 26.01B |
| Gross Margin | 75.2% | 75.7% | 70.1% | 61.5% | 70.8% |
| Research & Development | 6.32B | 4.43B | 4.78B | 5.96B | 6.97B |
| Selling, General & Admin | 5.37B | 5.41B | 6.18B | 7.1B | 7.05B |
| Operating Expenses | 11.89B | 10.35B | 11.84B | 13.31B | 15.34B |
| Depreciation & Amortization | 3.4B | 3.42B | 4.07B | 5.59B | 5.17B |
| EBITDA | 11.3B | 12.17B | 14.8B | 13.36B | 16.9B |
| EBITDA Margin | 43.5% | 46.2% | 52.5% | 40.0% | 46.0% |
| Operating Income | 7.64B | 9.57B | 7.9B | 7.26B | 10.68B |
| Operating Margin | 29.4% | 36.3% | 28.0% | 21.7% | 29.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.2B | 1.41B | 2.88B | 3.16B | 2.76B |
| Other Income / Expenses | (938M) | (2.22B) | (42M) | (2.65B) | (1.7B) |
| Income Before Tax | 6.7B | 7.35B | 7.86B | 4.61B | 8.98B |
| Pre-Tax Margin | 25.8% | 27.9% | 27.9% | 13.8% | 24.4% |
| Income Tax Expense | 808M | 794M | 1.14B | 519M | 1.27B |
| Net Income | 5.89B | 6.55B | 6.72B | 4.09B | 7.71B |
| Net Margin | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% |
| EPS (Basic) | 10.34 | 12.18 | 12.56 | 7.62 | 14.33 |
| EPS (Diluted) | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 |
| Weighted Avg Shares | 570M | 538M | 535M | 541M | 538M |
| Weighted Avg Shares (Diluted) | 573M | 541M | 538M | 541M | 542M |
Amgen Inc.
NASDAQ:AMGN
Intrinsic Alpha fair value
Locked
Current Price
$443.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.